Skip to content

Effects of Dezocine with different doses on Prevention of Propofol Injection Pain: a Randomized Controlled Trial

Effects of Dezocine with different doses on Prevention of Propofol Injection Pain: a Randomized Controlled Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-17011234
Enrollment
Unknown
Registered
2017-04-24
Start date
2017-05-01
Completion date
Unknown
Last updated
2020-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Propofol Injection Pain

Interventions

Group 1:2 ml saline
Group 2:2 ml 20mg lidocaine
Group 3:2ml 40mg lidocaine
Group 4:2ml 2mg dezocine
Group 5:2ml 4mg dezocine

Sponsors

Fudan University Shanghai Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Aged 18-80 years; 2) ASA I-II; 3) Elective surgery under general anesthesia; 4) Induction through the vein in the forearm; 5) All patients can understand and obey the study program, communicate well and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Patients with a history of hepatic or renal insufficiency, severe neurological or cardiovascular disease; 2) patients with obesity or difficult airway; 3) Pregnant patients; 4) patients with peripheral phlebitis; 5) Patients with drug abuse or on medication with analgesics; 6) Patients allergic to dezocine, lidocaine and other drugs; 7) Patients with psychologial disease or cognitive disorder, can't obey the study program, can't communicate well; 8) Patients refuse to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
four-point scale for pain assessment of propofol injection pain;

Countries

China

Contacts

Public ContactSun zhirong

Fudan University Shanghai Cancer Center

sunzij781101@163.com+86 18017317650

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026